Catalyst Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Catalyst Biosciences has a total shareholder equity of $3.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $10.0M and $6.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$2.23m |
Equity | US$3.52m |
Total liabilities | US$6.45m |
Total assets | US$9.96m |
Recent financial health updates
Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky
Jan 11Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely
May 18We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely
Feb 01Recent updates
Catalyst Biosciences declares special one-time dividend of $1.43
Aug 25Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock
Aug 15Catalyst Biosciences plans to distribute $65M cash to stockholders
Jun 29Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky
Jan 11Circling Back On Catalyst Biosciences
Dec 08Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why
Jun 03Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely
May 18Catalyst Biosciences EPS misses by $0.12, beats on revenue
May 06Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?
Mar 09We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely
Feb 01Catalyst Biosciences announces closing of $50M capital raise
Jan 29Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?
Dec 28Catalyst Biosciences' MarzAA fast track'd for episodic bleeding in hemophilia patients
Dec 02What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay
Dec 02Catalyst Biosciences (CBIO) Presents At Stifel 2020 Virtual Healthcare Conference - Slideshow
Nov 18Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next
Nov 14Financial Position Analysis
Short Term Liabilities: CBIO's short term assets ($5.1M) exceed its short term liabilities ($1.8M).
Long Term Liabilities: CBIO's short term assets ($5.1M) exceed its long term liabilities ($4.7M).
Debt to Equity History and Analysis
Debt Level: CBIO is debt free.
Reducing Debt: CBIO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CBIO has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: Insufficient data to determine if CBIO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.